AMGN
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FAMGN.O%2Fkey-developments%2Farticle%2F2469067&ei=knKaUpjmBeTX0QGcJA&usg=AFQjCNEkoE91p5IgYvPEnF_vL9v9FlWVpA
Amgen, Inc. Announces To Acquire Micromet, Inc
Thursday, 26 Jan 2012 08:01am EST
Amgen, Inc. and Micromet, Inc. announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for USD11 per share in cash. The transaction, which values Micromet at approximately USD1.16 billion, was unanimously approved by both the Amgen and Micromet Boards of Directors. The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.Â 
